|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DAB2 |
Gene summary for DAB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DAB2 | Gene ID | 1601 |
| Gene name | DAB adaptor protein 2 | |
| Gene Alias | DOC-2 | |
| Cytomap | 5p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P98082 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1601 | DAB2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.86e-16 | 5.81e-01 | -0.0811 |
| 1601 | DAB2 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.91e-06 | 3.85e-01 | -0.1088 |
| 1601 | DAB2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.86e-17 | 5.47e-01 | -0.059 |
| 1601 | DAB2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.58e-02 | 2.27e-01 | -0.0179 |
| 1601 | DAB2 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.64e-04 | 2.51e-01 | 0.096 |
| 1601 | DAB2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.53e-06 | 4.11e-01 | 0.0338 |
| 1601 | DAB2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.60e-29 | 6.31e-01 | 0.0674 |
| 1601 | DAB2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.07e-04 | 4.16e-01 | 0.0112 |
| 1601 | DAB2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.33e-05 | 3.29e-01 | 0.0588 |
| 1601 | DAB2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.35e-08 | 2.59e-01 | 0.294 |
| 1601 | DAB2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.84e-09 | 4.11e-01 | 0.281 |
| 1601 | DAB2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.43e-05 | 2.24e-01 | 0.3859 |
| 1601 | DAB2 | A002-C-021 | Human | Colorectum | FAP | 8.00e-03 | 1.47e-01 | 0.1171 |
| 1601 | DAB2 | P2T-E | Human | Esophagus | ESCC | 2.88e-05 | 5.46e-02 | 0.1177 |
| 1601 | DAB2 | P9T-E | Human | Esophagus | ESCC | 5.94e-06 | 2.88e-01 | 0.1131 |
| 1601 | DAB2 | P16T-E | Human | Esophagus | ESCC | 2.03e-13 | 1.29e-01 | 0.1153 |
| 1601 | DAB2 | P32T-E | Human | Esophagus | ESCC | 3.62e-19 | 6.73e-01 | 0.1666 |
| 1601 | DAB2 | P37T-E | Human | Esophagus | ESCC | 2.19e-10 | 2.23e-01 | 0.1371 |
| 1601 | DAB2 | P40T-E | Human | Esophagus | ESCC | 1.61e-02 | 1.62e-01 | 0.109 |
| 1601 | DAB2 | P44T-E | Human | Esophagus | ESCC | 7.96e-06 | 3.88e-01 | 0.1096 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006082825 | Thyroid | ATC | regulation of canonical Wnt signaling pathway | 134/6293 | 253/18723 | 1.49e-10 | 4.56e-09 | 134 |
| GO:006007025 | Thyroid | ATC | canonical Wnt signaling pathway | 154/6293 | 303/18723 | 3.68e-10 | 1.02e-08 | 154 |
| GO:0048545210 | Thyroid | ATC | response to steroid hormone | 168/6293 | 339/18723 | 7.21e-10 | 1.88e-08 | 168 |
| GO:0030100111 | Thyroid | ATC | regulation of endocytosis | 113/6293 | 211/18723 | 1.71e-09 | 4.22e-08 | 113 |
| GO:190437526 | Thyroid | ATC | regulation of protein localization to cell periphery | 74/6293 | 125/18723 | 3.78e-09 | 8.66e-08 | 74 |
| GO:001648218 | Thyroid | ATC | cytosolic transport | 93/6293 | 168/18723 | 5.19e-09 | 1.15e-07 | 93 |
| GO:1905475111 | Thyroid | ATC | regulation of protein localization to membrane | 96/6293 | 175/18723 | 5.55e-09 | 1.22e-07 | 96 |
| GO:0030522112 | Thyroid | ATC | intracellular receptor signaling pathway | 134/6293 | 265/18723 | 7.58e-09 | 1.63e-07 | 134 |
| GO:0030177110 | Thyroid | ATC | positive regulation of Wnt signaling pathway | 80/6293 | 140/18723 | 8.75e-09 | 1.86e-07 | 80 |
| GO:000717823 | Thyroid | ATC | transmembrane receptor protein serine/threonine kinase signaling pathway | 170/6293 | 355/18723 | 1.40e-08 | 2.87e-07 | 170 |
| GO:000183722 | Thyroid | ATC | epithelial to mesenchymal transition | 87/6293 | 157/18723 | 1.50e-08 | 3.06e-07 | 87 |
| GO:001701522 | Thyroid | ATC | regulation of transforming growth factor beta receptor signaling pathway | 74/6293 | 128/18723 | 1.58e-08 | 3.20e-07 | 74 |
| GO:0045807111 | Thyroid | ATC | positive regulation of endocytosis | 61/6293 | 100/18723 | 1.80e-08 | 3.59e-07 | 61 |
| GO:190384422 | Thyroid | ATC | regulation of cellular response to transforming growth factor beta stimulus | 75/6293 | 131/18723 | 2.26e-08 | 4.39e-07 | 75 |
| GO:190382816 | Thyroid | ATC | negative regulation of cellular protein localization | 67/6293 | 117/18723 | 1.23e-07 | 2.06e-06 | 67 |
| GO:190307627 | Thyroid | ATC | regulation of protein localization to plasma membrane | 61/6293 | 104/18723 | 1.38e-07 | 2.26e-06 | 61 |
| GO:005110027 | Thyroid | ATC | negative regulation of binding | 86/6293 | 162/18723 | 2.41e-07 | 3.73e-06 | 86 |
| GO:007138328 | Thyroid | ATC | cellular response to steroid hormone stimulus | 103/6293 | 204/18723 | 4.32e-07 | 6.30e-06 | 103 |
| GO:004876221 | Thyroid | ATC | mesenchymal cell differentiation | 116/6293 | 236/18723 | 5.08e-07 | 7.30e-06 | 116 |
| GO:003051826 | Thyroid | ATC | intracellular steroid hormone receptor signaling pathway | 65/6293 | 116/18723 | 5.58e-07 | 7.93e-06 | 65 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| DAB2 | INCAF | Skin | ADJ | CTSL,HMGA1,CCDC80, etc. | 1.92e-01 |  |
| DAB2 | INCAF | Skin | SCCIS | CTSL,HMGA1,CCDC80, etc. | 2.45e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DAB2 | SNV | Missense_Mutation | c.1639N>A | p.Gly547Ser | p.G547S | P98082 | protein_coding | tolerated(0.28) | benign(0.043) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DAB2 | SNV | Missense_Mutation | rs376782436 | c.1729G>A | p.Ala577Thr | p.A577T | P98082 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| DAB2 | SNV | Missense_Mutation | novel | c.1797N>A | p.Phe599Leu | p.F599L | P98082 | protein_coding | deleterious(0.03) | possibly_damaging(0.459) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DAB2 | SNV | Missense_Mutation | c.5C>T | p.Ser2Phe | p.S2F | P98082 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DAB2 | SNV | Missense_Mutation | c.796N>G | p.Pro266Ala | p.P266A | P98082 | protein_coding | deleterious(0.05) | possibly_damaging(0.62) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DAB2 | SNV | Missense_Mutation | c.2277N>C | p.Glu759Asp | p.E759D | P98082 | protein_coding | tolerated(1) | benign(0) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| DAB2 | SNV | Missense_Mutation | novel | c.1546N>G | p.Thr516Ala | p.T516A | P98082 | protein_coding | tolerated(0.93) | benign(0) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| DAB2 | SNV | Missense_Mutation | novel | c.1931N>T | p.Gly644Val | p.G644V | P98082 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-E9-A3HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| DAB2 | insertion | Nonsense_Mutation | novel | c.1317_1318insTGACTCTTTTGCTTTTGCTCATAAAATGATGATGCATC | p.Gly440Ter | p.G440* | P98082 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| DAB2 | insertion | Nonsense_Mutation | novel | c.1581_1582insACTTTGATGCTAATCAACTATTGA | p.Met527_Ala528insThrLeuMetLeuIleAsnTyrTer | p.M527_A528insTLMLINY* | P98082 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |